LPTX is currently developing the following drugs: Bevacizumab, Folfiri, Folfox, Dkn-01, Fluorouracil, Oxaliplatin, Dkn-01 300Mg, Dkn-01 600Mg, Dkn-01 400Mg, Tislelizumab 200Mg, Tislelizumab 400Mg, Capecitabine 1000Mg/ M2 Twice Daily (Bid), Leucovorin Calcium, Paclitaxel, 300Mg Dkn-01, 600Mg Dkn-01. These drug candidates are in various stages of clinical development as the company works toward FDA approval.